Skip to main content

Ravicti Disease Interactions

There are 4 disease interactions with Ravicti (glycerol phenylbutyrate).

Moderate

Glycerol phenylbutyrate (applies to Ravicti) fat malabsorption

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Malabsorption Syndrome

Pancreatic enzymes hydrolyze glycerol phenylbutyrate in the small intestine. Intestinal disease resulting in fat malabsorption may result in reduced digestion of glycerol phenylbutyrate. It is recommended to monitor the ammonia levels closely in patients with pancreatic insufficiency or intestinal malabsorption.

References

  1. (2013) "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc
Moderate

Glycerol phenylbutyrate (applies to Ravicti) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Patients with hepatic impairment may have higher plasma phenylacetate (PAA) and phenylacetate to phenylacetylglutamine (PAGN) ratio due to a reduced conversion capability of PAA to PAGN in the liver. Patients with moderate to severe hepatic impairment may require lower dosages of glycerol phenylbutyrate than normal to control the patient's ammonia levels. Caution is recommended in patients with hepatic impairment as no studies have been conducted.

References

  1. (2013) "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc
Moderate

Glycerol phenylbutyrate (applies to Ravicti) neuropathy

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Peripheral Neuropathy

The major metabolite of glycerol phenylbutyrate, PAA, is associated with neurotoxicity. Cases of exacerbation of preexisting neuropathy have been documented in patients using this agent. It is recommended to exercise caution when using glycerol phenylbutyrate in patients with neuropathy.

References

  1. (2013) "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc
Moderate

Glycerol phenylbutyrate (applies to Ravicti) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The efficacy and safety of glycerol phenylbutyrate in patients with renal impairment are unknown. It is recommended to monitor ammonia levels closely when using this agent in patients with impaired renal function.

References

  1. (2013) "Product Information. Ravicti (glycerol phenylbutyrate)." Hyperion Therapeutics Inc

Ravicti drug interactions

There are 260 drug interactions with Ravicti (glycerol phenylbutyrate).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer